Cleared Traditional

K170854 - HemosIL AcuStar HIT-IgG(PF4-H), HemosIL AcuStar HIT Controls

K170854 is an FDA 510(k) clearance for HemosIL AcuStar HIT-IgG(PF4-H), manufactured by Instrumentation Laboratory CO. The device is a Class 2 Hematology device with product code LCO cleared through the Traditional 510(k) pathway after a 170-day FDA review.

K170854 · Instrumentation Laboratory CO · Hematology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Sep 2017
Decision
170d
Days
Class 2
Risk

K170854 is an FDA 510(k) clearance for the HemosIL AcuStar HIT-IgG(PF4-H), HemosIL AcuStar HIT Controls. Classified as Platelet Factor 4 Radioimmunoassay (product code LCO), Class II - Special Controls.

Submitted by Instrumentation Laboratory CO (Bedford, US). The FDA issued a Cleared decision on September 8, 2017 after a review of 170 days - an extended review cycle.

This device falls under the Hematology FDA review panel, regulated under 21 CFR 864.7695 - the FDA hematology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Hematology review framework, consistent with the majority of Class II 510(k) submissions.

View all Instrumentation Laboratory CO devices

FDA 510(k) Submission Details - K170854

510(k) Number K170854 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received March 22, 2017
Decision Date September 08, 2017
Days to Decision 170 days
Submission Type Traditional
Review Panel Hematology (HE)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
57d slower than avg
Panel avg: 113d · This submission: 170d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

LCO Device Classification - Class 2, Special Controls

Product Code LCO Platelet Factor 4 Radioimmunoassay
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 864.7695
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Hematology devices follow this clearance model.

Regulatory Peers - LCO Platelet Factor 4 Radioimmunoassay

All 8
Devices cleared under the same product code (LCO) and FDA review panel - the closest regulatory comparables to K170854.
HemosIL CL HIT-IgG(PF4-H)
K243374 · Instrumentation Laboratory (IL) Co. · Jan 2025
PF4 Enhanced assay
K201570 · Immucor Gti Diagnostics, Inc. · Sep 2020
PF4 IgG assay
K201311 · Immucor Gti Diagnostics, Inc. · Jun 2020
HemosIL HIT-Ab(PF4-H), HemosIL HIT-Ab(PF4-H) Controls
K153137 · Instrumentation Laboratory CO · Jul 2016
ASSERACHROM HPIA TEST KIT
K003767 · Diagnostica Stago, Inc. · Feb 2001
GTI-PF4 ELISA
K983379 · Genetic Testing Institute · Mar 1999